15.2 Anemias in Women: Iron Deficiency, Microcytic & Macrocytic Anemias
Key Takeaways
World Health Organization (WHO) and ACOG define anemia in non-pregnant women as hemoglobin <12.0 g/dL (hematocrit <36%); in pregnant women, gestational plasma volume expansion lowers diagnostic thresholds to hemoglobin <11.0 g/dL (hematocrit <33%) in the first and third trimesters, and <10.5 g/dL (hematocrit <32%) in the second trimester.
Iron deficiency anemia (IDA) is the most prevalent cause of microcytic anemia (MCV <80 fL) in women, characterized by serum ferritin <30 ng/mL (the most sensitive and specific diagnostic marker), elevated total iron-binding capacity (TIBC), transferrin saturation <16%–20%, and elevated red cell distribution width (RDW >14.5%).
Thalassemia minor presents with mild microcytosis (MCV <75 fL) disproportionate to mild anemia, a normal or high total RBC count (>5.0 million/mcL), normal RDW, and a Mentzer index (MCV/RBC) <13, confirmed by hemoglobin electrophoresis demonstrating elevated HbA2 (>3.5%) in beta-thalassemia trait.
Macrocytic anemias (MCV >100 fL) are categorized into megaloblastic (impaired DNA synthesis with hypersegmented neutrophils and oval macrocytes) and non-megaloblastic (hypothyroidism, liver disease, reticulocytosis); Vitamin B12 deficiency causes neurological deficits and elevated levels of both methylmalonic acid (MMA) and homocysteine, whereas folate deficiency presents with normal MMA and elevated homocysteine without neurologic compromise.
First-line IDA therapy consists of oral ferrous sulfate (324 mg / 65 mg elemental iron) dosed once daily or every other day with ascorbic acid to prevent hepcidin surges; intravenous iron formulations (iron sucrose, ferric carboxymaltose) are indicated for severe second- or third-trimester IDA, oral intolerance, malabsorption (celiac disease, bariatric surgery), or heavy ongoing uterine bleeding.
Diagnostic Definitions & Gestational Hemodilution: WHO & ACOG Criteria
Anemia represents a reduction in circulating red blood cell (RBC) mass, hemoglobin (Hb) concentration, or hematocrit (Hct), impairing systemic tissue oxygenation. Diagnostic thresholds vary based on biological sex and gestational status:
| Patient Population | Hemoglobin (Hb) Cutoff | Hematocrit (Hct) Cutoff | Diagnostic Authority |
|---|---|---|---|
| Non-Pregnant Adult Females | <12.0 g/dL (120 g/L) | <36.0% (0.36) | WHO, ACOG, CDC |
| Pregnant Females: First Trimester | <11.0 g/dL (110 g/L) | <33.0% (0.33) | ACOG, CDC, WHO |
| Pregnant Females: Second Trimester | <10.5 g/dL (105 g/L) | <32.0% (0.32) | ACOG, CDC |
| Pregnant Females: Third Trimester | <11.0 g/dL (110 g/L) | <33.0% (0.33) | ACOG, CDC, WHO |
| Postpartum Females | <10.0 g/dL (100 g/L) | <30.0% (0.30) | ACOG, WHO |
Physiological Hemodilution vs. Pathological Anemia
During normal gestation, maternal plasma volume expands by 45% to 50%, while erythropoietin-stimulated red blood cell mass expands by only 20% to 30%. This disproportionate fluid expansion creates physiological hemodilution ("physiologic anemia of pregnancy"), reaching a hemoglobin nadir at 24 to 28 weeks. Hemoglobin concentrations falling below 10.5 g/dL in the second trimester or below 11.0 g/dL in the first or third trimesters represent true pathological anemia requiring clinical intervention to avoid maternal exhaustion, cardiac strain, preterm delivery, and low birth weight.
Microcytic Anemias: Iron Deficiency, Thalassemia & Chronic Disease
Mean Corpuscular Volume (MCV) categorizes anemias into microcytic (<80 fL), normocytic (80–100 fL), and macrocytic (>100 fL). Microcytic anemias result from impaired hemoglobin synthesis:
1. Iron Deficiency Anemia (IDA)
Iron deficiency is the leading cause of anemia worldwide, accounting for >50% of cases in women. Etiologies in females include heavy menstrual bleeding (AUB/menorrhagia), high gestational demands (~1,000 mg total pregnancy iron requirement: 300 mg fetus/placenta, 500 mg RBC expansion, 200 mg excretion), nutritional insufficiency, and malabsorption (celiac disease, H. pylori, bariatric bypass).
- Diagnostic Profile:
- Serum Ferritin: The single most sensitive and specific marker; ferritin <30 ng/mL confirms iron deficiency (<15 ng/mL absolute exhaustion; <30–45 ng/mL in pregnancy).
- Total Iron-Binding Capacity (TIBC): Elevated (>400 mcg/dL) due to compensatory hepatic transferrin synthesis.
- Transferrin Saturation (TSAT): Depressed (<16%–20%).
- Red Cell Distribution Width (RDW): Elevated (>14.5%), reflecting anisocytosis.
- Blood Smear: Microcytic, hypochromic RBCs with central pallor, anisopoikilocytosis, and pencil cells.
2. Thalassemia Minor / Trait (Alpha or Beta)
Inherited quantitative globin chain deficiencies characterized by mild microcytic anemia (Hb 10.0–11.5 g/dL) with strikingly low MCV (<75 fL) disproportionate to the mild anemia, accompanied by a normal or high total RBC count (>5.0 million/mcL) and normal RDW (<14%).
- Mentzer Index (MCV / RBC count): An index <13 strongly indicates thalassemia trait, whereas an index >13 suggests iron deficiency anemia.
- Hemoglobin Electrophoresis: Confirms beta-thalassemia trait via elevated HbA2 >3.5% (normal 1.5%–3.5%) and variable HbF (1%–5%). Alpha-thalassemia trait exhibits normal adult electrophoresis, requiring alpha-globin gene DNA deletion testing.
3. Anemia of Chronic Disease / Chronic Inflammation (ACD)
Driven by inflammatory cytokines (IL-6, TNF-alpha) stimulating hepatic synthesis of hepcidin, which degrades ferroportin channels, trapping iron within macrophages and enterocytes. Laboratory profile: normal or elevated ferritin (>100 ng/mL), low TIBC (<250 mcg/dL), low serum iron, and low-to-normal TSAT.
| Laboratory Parameter | Iron Deficiency Anemia (IDA) | Thalassemia Minor / Trait | Anemia of Chronic Disease (ACD) |
|---|---|---|---|
| MCV | Low (<80 fL; proportional) | Markedly Low (<75 fL; disproportionate) | Normal to mildly low (75–85 fL) |
| Serum Ferritin | Low (<30 ng/mL) | Normal to elevated (50–300 ng/mL) | Normal to Elevated (>100 ng/mL) |
| TIBC | Elevated (>400 mcg/dL) | Normal (250–400 mcg/dL) | Low (<250 mcg/dL) |
| TSAT | Low (<16%–20%) | Normal to elevated (>20%) | Low-to-normal (15%–25%) |
| RDW | Elevated (>14.5%) | Normal (<14.0%) | Normal to mildly elevated |
| Mentzer Index | >13 | <13 | Variable (>13) |
Normocytic Anemias & Reticulocyte Dynamics
Normocytic anemias (MCV 80–100 fL) are categorized by the reticulocyte production index (RPI):
- Hyperproliferative (RPI >2 or Reticulocytes >2%): Indicates accelerated destruction or loss. Hallmark of hemolytic anemias: elevated indirect bilirubin, elevated lactate dehydrogenase (LDH), suppressed serum haptoglobin (haptoglobin binds free intravascular hemoglobin), and positive Coombs / Direct Antiglobulin Test (DAT) in autoimmune hemolysis.
- Hypoproliferative (RPI <2 or Reticulocytes <2%): Indicates impaired erythrocyte production. Common etiologies include chronic kidney disease (CKD) with deficient peritubular erythropoietin secretion, early nutritional deficiency, or bone marrow infiltration.
Macrocytic Anemias: Megaloblastic vs. Non-Megaloblastic Differentiation
Macrocytic anemia is defined by an MCV >100 fL, divided by peripheral blood smear morphology into megaloblastic and non-megaloblastic forms:
1. Megaloblastic Anemia (Impaired DNA Synthesis)
Defective purine and thymidine synthesis delays nuclear replication relative to cytoplasmic RNA synthesis (nuclear-cytoplasmic dyssynchrony). Smear demonstrates macro-ovalocytes and hypersegmented neutrophils (≥1 neutrophil with ≥6 lobes, or ≥5% with ≥5 lobes).
| Parameter | Vitamin B12 (Cobalamin) Deficiency | Folate (Vitamin B9) Deficiency |
|---|---|---|
| Primary Causes | Pernicious anemia (anti-intrinsic factor antibodies); terminal ileal resection/Crohn disease; strict vegan diet; bariatric surgery; long-term metformin (>3–4 years) or PPI use. | Dietary deficiency (lack of green leafy vegetables); alcohol use disorder; antifolate drugs (methotrexate, trimethoprim, phenytoin); malabsorption; pregnancy. |
| Neurological Symptoms | PRESENT: Subacute combined degeneration of the spinal cord (paresthesias, sensory ataxia, loss of vibratory/position sense, spasticity, dementia). | ABSENT: No neurological deficits. (Gestational deficiency causes fetal neural tube defects). |
| Methylmalonic Acid (MMA) | ELEVATED (Cobalamin required for methylmalonyl-CoA mutase). | NORMAL |
| Homocysteine | ELEVATED | ELEVATED |
Important
Never treat macrocytic anemia with high-dose folic acid alone without excluding Vitamin B12 deficiency. Supplemental folate can correct hematologic abnormalities while allowing irreversible subacute combined degeneration of the spinal cord to progress silently.
2. Non-Megaloblastic Macrocytic Anemia (Normal DNA Synthesis)
Normal DNA synthesis featuring round macrocytes without hypersegmented neutrophils. Etiologies include alcohol use disorder, hepatic cirrhosis, primary hypothyroidism, and marked reticulocytosis.
Evidence-Based Iron Repletion: Oral Dosing & Intravenous Indications
Oral Iron Dosing Dynamics
- Alternate-Day Dosing: A medicinal iron dose triggers an acute rise in hepatic hepcidin that persists for 24 to 48 hours, blocking subsequent intestinal ferroportin channels. Dosing ferrous sulfate (324 mg / 65 mg elemental iron) once daily or every other day avoids hepcidin spikes, increases fractional iron absorption by >30%, and dramatically reduces gastrointestinal adverse effects (nausea, constipation, dark stools).
- Administration Rules: Take on an empty stomach with water or vitamin C (ascorbic acid 250–500 mg) to enhance absorption. Avoid concurrent calcium, antacids, dairy, tea, or coffee.
- Response: Reticulocytosis peaks at 7 to 10 days; hemoglobin rises by 1.0 to 2.0 g/dL every 2 to 4 weeks. Continue oral therapy for 3 to 6 months after hemoglobin normalizes to replenish tissue ferritin (>50 ng/mL).
Intravenous Iron Formulations
Modern IV formulations (iron sucrose, ferric carboxymaltose) bypass intestinal absorption directly into transferrin. Key clinical indications in women's health:
- Severe iron deficiency anemia in the late second or third trimester (Hb <9.0–10.0 g/dL after 28 weeks), where rapid repletion is mandatory prior to delivery.
- Oral iron intolerance causing intractable gastrointestinal side effects.
- Gastrointestinal malabsorption: active celiac disease, inflammatory bowel disease, post-Roux-en-Y gastric bypass.
- Intractable heavy menstrual bleeding exceeding oral absorption capacity.
A 26-year-old female of Mediterranean ancestry presents for an initial preconception consultation. She is asymptomatic and active. A complete blood count reveals: Hemoglobin 10.6 g/dL, Hematocrit 32.8%, MCV 65 fL, MCH 20.8 pg, RBC count 5.3 million/mcL, and RDW 12.6% (normal reference: 11.5%–14.5%). Serum iron studies demonstrate: Ferritin 68 ng/mL (normal), Serum Iron 84 mcg/dL, and Total Iron-Binding Capacity (TIBC) 320 mcg/dL. The calculated Mentzer index (MCV / RBC) is 12.3. What is the most likely diagnosis, and what is the next appropriate clinical diagnostic step?
Iron deficiency anemia; initiate oral ferrous sulfate 324 mg twice daily with ascorbic acid.
Anemia of chronic disease; order serum inflammatory markers (ESR and CRP) and screen for occult autoimmune disease.
Sideroblastic anemia; perform an immediate bone marrow aspirate to evaluate for ringed sideroblasts.
Beta-thalassemia trait (minor); obtain quantitative hemoglobin electrophoresis to evaluate for elevated HbA2.
A 36-year-old female presents to the ambulatory clinic complaining of 4 months of progressive fatigue, exertional shortness of breath, and bilateral painful "pins-and-needles" sensations and numbness in her feet. Her surgical history is notable for a terminal ileal resection 4 years ago for complicated Crohn disease. Physical examination reveals conjunctival pallor, a smooth erythematous tongue (glossitis), decreased vibratory sensation and proprioception in both lower extremities, and an unsteady tandem gait. Laboratory evaluation reveals: Hemoglobin 8.6 g/dL, Hematocrit 25.8%, and MCV 114 fL. The peripheral blood smear shows macro-ovalocytes and multiple neutrophils displaying 6 to 7 nuclear lobes. Which set of serum biochemical findings is most consistent with this patient's condition?
Normal serum cobalamin, low serum folate, normal methylmalonic acid (MMA), and elevated serum homocysteine.
Low serum cobalamin, elevated serum methylmalonic acid (MMA), and elevated serum homocysteine.
Low serum cobalamin, normal serum methylmalonic acid (MMA), and normal serum homocysteine.
Low serum folate, low serum ferritin, elevated TIBC, and normal methylmalonic acid (MMA).
A 31-year-old female at 32 weeks gestation presents for routine antepartum evaluation complaining of profound exhaustion, lightheadedness, and restless legs syndrome. Her surgical history includes a Roux-en-Y gastric bypass 3 years ago. For the past 8 weeks, she was prescribed oral ferrous sulfate 324 mg daily, but she reports severe intractable nausea, abdominal cramping, and worsening constipation leading to poor adherence. A repeat complete blood count and iron panel demonstrate: Hemoglobin 8.4 g/dL, Hematocrit 25.0%, MCV 71 fL, Serum ferritin 7 ng/mL, and Transferrin saturation (TSAT) 6%. What is the most appropriate evidence-based clinical management plan?
Discontinue oral iron, reassure the patient that physiological hemodilution is expected, and reassess hemoglobin postpartum.
Increase oral ferrous sulfate to 324 mg three times daily and co-prescribe oral docusate sodium.
Initiate intravenous iron therapy (such as ferric carboxymaltose or iron sucrose).
Perform an emergency transfusion of two units of packed red blood cells immediately.
Sections you finish are checked off in the contents.